wsava
vaccin
guidelin
group
vgg
conven
aim
produc
global
vaccin
guidelin
dog
cat
would
consid
intern
differ
econom
societ
factor
impact
keep
small
companion
anim
wsava
guidelin
therefor
intend
much
broader
scope
produc
north
america
american
academi
felin
practition
scherk
et
al
american
anim
hospit
associ
welborn
et
al
europ
advisori
board
cat
diseas
hosi
et
al
first
wsava
guidelin
publish
updat
day
et
al
accompani
document
written
owner
breeder
pet
dog
cat
vgg
focus
dog
cat
infecti
diseas
vaccinolog
asian
contin
produc
region
recommend
aspect
vaccin
asian
practition
day
et
al
vgg
work
updat
global
canin
felin
vaccin
guidelin
present
document
format
much
content
revis
remain
similar
guidelin
publish
howev
specif
chang
current
document
includ
mortal
small
anim
although
difficult
obtain
accur
figur
even
develop
countri
estim
pet
anim
popul
vaccin
significantli
less
develop
nation
global
econom
recess
impact
uptak
prevent
healthcar
pet
owner
develop
countri
survey
data
suggest
recent
declin
vaccin
anon
small
anim
medicin
slow
grasp
concept
herd
immun
vaccin
individu
pet
anim
import
protect
individu
reduc
number
suscept
anim
region
popul
thu
preval
diseas
herd
immun
relat
use
core
vaccin
provid
long
mani
year
doi
highli
depend
percentag
anim
popul
vaccin
number
vaccin
occur
annual
therefor
everi
effort
made
vaccin
higher
percentag
cat
dog
core
vaccin
simpli
possibl
induc
better
immun
individu
anim
give
repeat
vaccin
ie
dog
receiv
core
mlv
vaccin
everi
year
equal
well
protect
compar
one
receiv
vaccin
annual
bohm
et
al
mouzin
et
al
mitchel
et
al
may
necessarili
case
felin
core
vaccin
see
recent
year
reemerg
concept
one
health
also
impact
field
vaccinolog
manag
infecti
diseas
collabor
interact
human
medic
anim
environment
healthcar
profession
provid
ration
costeffect
goal
time
major
newli
emerg
human
infecti
diseas
propos
deriv
wild
domest
anim
sourc
gibb
wsava
embrac
one
health
concept
establish
one
health
committe
day
work
overlap
vgg
tackl
major
small
companion
anim
zoonos
canin
rabi
leishmaniosi
second
major
concept
regard
vaccin
dog
cat
recognit
aim
reduc
vaccin
load
individu
anim
order
minim
potenti
advers
reaction
vaccin
product
reduc
time
financi
burden
client
veterinarian
unjustifi
veterinari
medic
procedur
reason
seen
develop
vaccin
guidelin
base
ration
analysi
vaccin
requir
pet
propos
vaccin
consid
core
noncor
natur
extent
categor
product
base
avail
scientif
evid
person
experi
concert
effort
introduc
effect
companion
anim
diseas
surveil
global
scale
would
provid
definit
basi
recommend
vaccin
usag
day
et
al
parallel
categor
vaccin
push
toward
market
product
extend
doi
reduc
unnecessari
administr
vaccin
therebi
improv
vaccin
safeti
chang
necessit
frameshift
mindset
veterinari
practition
becom
accept
norm
mani
countri
follow
vgg
guidelin
prepar
consid
optimum
model
commit
pet
owner
will
abl
bring
anim
veterinarian
full
recommend
cours
vaccin
vgg
awar
less
commit
abl
pet
owner
everi
countri
countri
sever
financi
societ
constraint
often
determin
natur
vaccin
cours
administ
situat
exampl
decis
must
made
individu
pet
may
receiv
singl
core
vaccin
lifetim
vgg
would
emphasis
optim
given
time
anim
capabl
respond
immunolog
ie
greater
week
age
vgg
addit
consid
vaccin
shelter
situat
guidelin
propos
consid
provid
optimum
level
protect
highli
suscept
anim
vgg
also
recognis
mani
shelter
run
limit
financi
support
may
constrain
extent
vaccin
use
minimum
vaccin
protocol
situat
would
singl
administr
core
vaccin
time
admiss
shelter
document
seek
address
current
issu
canin
felin
vaccinolog
suggest
practic
measur
veterinari
profess
may
move
toward
ration
use
vaccin
speci
import
messag
vgg
therefor
encapsul
follow
statement
aim
vaccin
everi
anim
core
vaccin
noncor
vaccin
given
frequent
deem
necessari
discuss
specif
vaccin
guidelin
brief
review
type
small
companion
anim
vaccin
avail
justifi
vaccin
may
consid
simpli
either
infecti
noninfecti
natur
infecti
vaccin
use
dog
cat
contain
organ
attenu
reduc
virul
ie
modifi
live
viru
mlv
attenu
vaccin
organ
intact
viabl
induc
immun
induc
lowlevel
infect
replic
within
anim
without
produc
signific
tissu
patholog
clinic
sign
infecti
diseas
infecti
vaccin
advantag
effect
induc
immun
relev
anatom
site
administ
parenter
like
induc
robust
cellmedi
humor
antibodymedi
immun
infecti
vaccin
administ
journal
small
anim
practic
vol
januari
wsava
directli
mucos
site
ie
intranas
oral
vaccin
even
effect
induc
relev
protect
mucos
immun
recombin
vector
vaccin
ie
live
vector
organ
carri
genet
materi
encod
antigen
target
pathogen
may
also
consid
infecti
howev
vector
organ
relev
pathogen
dog
cat
administ
anim
lack
maternallyderiv
antibodi
mda
infecti
vaccin
gener
induc
protect
singl
dose
noninfecti
vaccin
also
known
kill
inactiv
vaccin
includ
subunit
nake
dna
vaccin
contain
inactiv
antigen
intact
viru
organ
natur
synthet
antigen
deriv
viru
organ
dna
encod
antigen
noninfecti
agent
unabl
infect
replic
induc
patholog
clinic
sign
infecti
diseas
gener
requir
adjuv
increas
potenc
usual
requir
multipl
dose
even
adult
anim
induc
protect
noninfecti
vaccin
administ
parenter
may
less
like
induc
cellmedi
humor
immun
gener
shorter
doi
compar
infecti
vaccin
basic
immun
schedul
guidelin
recommend
core
recommend
noncor
option
recommend
vaccin
gener
veterinari
practic
given
tabl
vgg
consid
core
vaccin
one
dog
throughout
world
must
receiv
recommend
interv
order
provid
lifelong
protect
infecti
diseas
global
signific
core
vaccin
dog
confer
protect
infect
canin
distemp
viru
cdv
canin
adenoviru
cav
type
canin
parvoviru
type
variant
vgg
recogn
particular
countri
identifi
addit
vaccin
consid
core
particular
exampl
vaccin
may
consid
core
countri
rabi
viru
geograph
area
infect
endem
dog
vaccin
routin
protect
pet
human
popul
vgg
strongli
endors
joint
statement
wsava
one
health
committe
intern
organis
anim
health
oie
set
target
global
elimin
canin
rabi
anon
mani
countri
rabi
vaccin
legal
requir
gener
also
requir
intern
pet
travel
noncor
vaccin
use
determin
basi
geograph
lifestyl
exposur
risk
individu
assess
riskbenefit
ratio
ie
risk
unvaccin
suscept
risk
vaccin
develop
advers
reaction
versu
benefit
protect
infect
question
recommend
vaccin
littl
scientif
justif
insuffici
evid
base
use
puppi
vaccin
booster
puppi
protect
mda
first
week
life
puppi
passiv
immun
wane
week
age
level
allow
activ
immun
puppi
poor
mda
may
vulner
capabl
respond
vaccin
earlier
age
other
may
possess
mda
high
titr
incap
respond
vaccin
week
age
friedrich
truyen
singl
primari
vaccin
polici
therefor
cover
possibl
situat
recommend
vgg
initi
core
vaccin
week
age
everi
week
week
age
older
therefor
number
puppi
primari
core
vaccin
determin
age
vaccin
start
select
interv
vaccin
possibl
schedul
outlin
tabl
recommend
vaccin
start
week
age
cours
four
primari
core
vaccin
would
administ
interv
three
would
requir
start
similar
interv
contrast
mani
vaccin
datasheet
continu
recommend
initi
cours
two
inject
core
vaccin
product
also
licens
week
finish
design
second
two
core
vaccin
given
week
age
rational
behind
protocol
permit
earli
social
puppi
diminish
risk
infecti
diseas
vgg
recogn
earli
social
essenti
behaviour
develop
dog
korbelik
et
al
avsab
protocol
ie
puppi
class
adopt
vigil
still
maintain
owner
allow
restrict
exposur
puppi
control
area
puppi
adult
appear
healthi
fulli
vaccin
particular
puppi
class
held
venu
away
veterinari
practic
altern
decid
veterinari
premis
must
use
floor
clean
disinfect
class
class
held
area
highli
traffick
dog
unknown
vaccin
diseas
statu
recent
us
studi
shown
minim
risk
amongst
vaccin
puppi
attend
social
class
stepita
et
al
vgg
recommend
whenev
possibl
last
puppi
primari
seri
core
vaccin
given
week
age
older
integr
part
core
vaccin
puppi
booster
vaccin
tradit
given
either
month
age
month
last
primari
seri
puppi
vaccin
main
aim
vaccin
ensur
protect
immun
respons
develop
dog
may
fail
respond
vaccin
primari
core
seri
rather
necessarili
boost
immun
respons
deliveri
vaccin
month
age
like
chosen
histor
conveni
time
request
owner
attend
practic
first
annual
health
check
therefor
impli
individu
puppi
fail
respond
primari
core
vaccin
puppi
may
unprotect
receiv
vaccin
might
account
occurr
infecti
diseas
eg
canin
parvovir
enter
proport
vaccin
puppi
less
month
age
vgg
reevalu
practic
suggest
veterinarian
might
wish
reduc
possibl
window
suscept
bring
forward
vaccin
week
week
age
inde
time
point
week
age
howev
week
age
provid
conveni
time
practic
requir
pet
owner
clearli
understand
recommend
indic
tabl
adopt
protocol
mean
vaccin
start
week
old
puppi
might
entail
five
vaccin
visit
first
month
life
core
vaccin
week
booster
anoth
core
vaccin
would
requir
least
anoth
year
new
recommend
vaccin
month
age
altern
vaccin
year
age
certainli
mutual
exclus
preclud
first
annual
health
check
mani
veterinarian
understand
keen
check
anim
care
around
time
reach
skelet
matur
dog
respond
vaccin
mlv
core
vaccin
maintain
solid
immun
immunolog
memori
mani
year
absenc
repeat
vaccin
bohm
et
al
mouzin
et
al
schultz
mitchel
et
al
follow
week
booster
subsequ
revaccin
given
interv
year
longer
emphas
triennial
adult
revaccin
gener
appli
kill
core
vaccin
except
rabi
noncor
vaccin
particularli
vaccin
contain
bacteri
antigen
thu
leptospira
bordetella
borrelia
lyme
diseas
product
also
parainfluenza
viru
compon
requir
frequent
booster
reliabl
protect
elli
krakowka
klaasen
et
al
elli
schuller
et
al
therefor
adult
dog
may
accord
guidelin
still
revaccin
annual
compon
vaccin
may
differ
year
typic
core
vaccin
current
administ
triennial
chosen
noncor
product
given
annual
vgg
awar
countri
multicompon
product
contain
core
noncor
combin
avail
vgg
would
encourag
manufactur
make
full
rang
reducedcompon
vaccin
least
separ
core
noncor
vaccin
mitchel
et
al
avail
wherev
possibl
adult
dog
receiv
complet
cours
core
vaccin
puppi
includ
week
booster
may
vaccin
regularli
adult
requir
singl
dose
mlv
core
vaccin
boost
immun
mouzin
et
al
mitchel
et
al
similarli
adopt
adult
dog
puppi
week
age
unknown
vaccin
histori
requir
singl
dose
mlv
core
vaccin
engend
protect
immun
respons
mani
vaccin
datasheet
advis
circumst
dog
requir
two
vaccin
puppi
practic
unjustifi
contrari
fundament
immunolog
principl
note
appli
noncor
vaccin
mani
requir
two
dose
adult
dog
particular
mention
made
canin
rabi
vaccin
vgg
recommend
countri
canin
rabi
endem
vaccin
dog
strongli
recommend
client
veterinarian
even
requir
law
revaccin
interv
canin
rabi
often
mandat
law
intern
avail
kill
rabi
vaccin
initi
produc
licens
doi
statut
requir
annual
revaccin
product
carri
doi
mani
countri
law
modifi
incorpor
chang
howev
countri
legal
requir
odd
vaccin
licens
other
neither
vaccin
licens
law
chang
final
countri
also
locallymanufactur
rabi
vaccin
doi
like
safe
extend
year
veterinarian
mind
law
access
product
confer
minimum
immun
nation
associ
might
lobbi
law
chang
match
current
scientif
evid
serolog
test
monitor
immun
canin
vaccin
sinc
public
guidelin
advanc
avail
rapid
simpl
inpractic
serolog
test
kit
detect
presenc
protect
antibodi
specif
cdv
cav
individu
dog
test
kit
complement
tradit
laboratorybas
modal
ie
viru
neutral
haemagglutin
inhibit
test
remain
gold
standard
serolog
test
two
commerci
produc
test
kit
avail
appli
valid
practic
shelter
set
gray
et
al
litster
et
al
test
kit
proven
popular
veterinarian
wish
abl
offer
client
altern
routin
core
revaccin
interv
kit
remain
rel
expens
unfortun
present
test
cost
dose
vaccin
neg
test
result
indic
dog
littl
antibodi
revaccin
recommend
seroneg
dog
fact
immun
falseneg
revaccin
would
unnecessari
would
make
rapid
substanti
anamnest
respons
vaccin
mouzin
et
al
howev
dog
detect
readili
anim
neg
result
regardless
test
use
consid
antibodi
potenti
suscept
infect
contrast
posit
test
result
would
lead
conclus
revaccin
requir
monitor
serum
antibodi
specif
canin
rabi
gener
use
manner
determin
revaccin
requir
mandat
law
laboratori
test
protect
rabi
antibodi
titr
consid
iuml
requir
intern
pet
travel
rabi
serolog
perform
recogn
refer
laboratori
serolog
test
cdv
cav
applic
determin
protect
immun
puppi
inform
revaccin
interv
adult
dog
manag
infecti
diseas
outbreak
shelter
dedic
owner
may
wish
confirm
puppi
protect
cours
primari
vaccin
complet
week
older
figur
serum
sampl
taken
least
week
final
vaccin
may
test
interv
ensur
mda
longer
present
even
slow
respond
puppi
seroconvert
seroposit
puppi
would
requir
week
booster
could
next
receiv
core
vaccin
year
later
seroneg
puppi
revaccin
retest
pup
test
neg
consid
nonrespond
possibl
incap
develop
protect
immun
test
antibodi
present
practic
way
ensur
puppi
immun
system
recogn
vaccin
antigen
vaccin
may
fail
induc
protect
immun
puppi
variou
reason
mda
neutral
vaccin
viru
common
reason
vaccin
failur
howev
last
vaccin
dose
given
week
age
older
mda
decreas
low
level
friedrich
truyen
activ
immun
succeed
puppi
vaccin
poorli
immunogen
poor
immunogen
may
reflect
rang
factor
stage
vaccin
design
manufactur
administr
anim
exampl
viru
strain
passag
histori
product
error
manufactur
particular
batch
product
may
caus
vaccin
failur
realiti
effect
rare
affect
vaccin
produc
larg
wellestablish
manufactur
market
vaccin
intern
manufactur
strict
requir
govern
regulatori
agenc
batch
potenc
test
releas
postmanufactur
factor
incorrect
storag
transport
interrupt
cold
chain
handl
disinfect
use
vaccin
veterinari
practic
may
result
inactiv
mlv
product
vgg
recogn
vaccin
husbandri
remain
issu
mani
countri
includ
simpl
guidelin
tabl
anim
poor
respond
immun
system
intrins
fail
recogn
vaccin
antigen
anim
fail
develop
antibodi
respons
repeat
revaccin
consid
genet
nonrespond
immunolog
nonrespons
genet
control
speci
certain
breed
dog
suspect
poorrespond
believ
unproven
high
suscept
recogn
certain
rottweil
dobermann
regardless
vaccin
histori
relat
part
high
preval
nonrespond
houston
et
al
usa
today
two
breed
seem
greater
number
nonrespond
breed
possibl
carrier
genet
trait
may
die
infect
dog
breed
may
low
nonrespond
antigen
exampl
uk
germani
nonrespond
phenotyp
remain
preval
amongst
rottweil
recent
studi
shown
breed
higher
proport
anim
fail
achiev
titr
rabi
antibodi
requir
pet
travel
kennedi
et
al
broad
estim
made
proport
genet
nonrespond
canin
popul
everi
dog
cdv
everi
dog
cav
everi
dog
serolog
test
determin
durat
immun
doi
antibodi
test
use
demonstr
doi
vaccin
core
vaccin
known
larg
major
dog
maintain
protect
antibodi
cdv
mani
year
numer
experiment
studi
support
observ
bohm
et
al
mouzin
et
al
schultz
mitchel
et
al
therefor
antibodi
absent
irrespect
serolog
test
use
dog
revaccin
unless
medic
reason
even
though
protect
immunolog
memori
antibodi
determin
vaccin
compon
limit
valu
short
time
period
antibodi
persist
eg
leptospira
product
lack
correl
serum
antibodi
protect
eg
leptospira
canin
parainfluenza
hartman
et
al
klaasen
et
al
elli
krakowka
vgg
recogn
present
serolog
test
might
rel
expens
howev
principl
evidencebas
veterinari
medicin
suggest
test
antibodi
statu
either
puppi
adult
dog
better
practic
simpli
administ
vaccin
booster
basi
would
safe
cost
less
vaccin
ie
activ
immun
domin
infecti
diseas
prevent
passiv
immun
continu
use
treatment
infecti
diseas
mani
countri
although
viru
infect
trigger
cellular
humor
immun
mainli
antibodi
respons
contribut
reduct
viral
load
recoveri
mani
viru
infect
antibodi
level
therefor
taken
correl
protect
viraemia
preexist
inject
antibodi
direct
surfac
structur
virion
bind
particl
neutral
infect
prepar
remov
therapeut
serum
immunoglobulin
prepar
use
passiv
immun
inject
subcutan
differ
anim
speci
quickli
reach
circul
unexpectedli
intraven
infus
plasma
serum
speci
found
work
well
local
infect
initi
bite
rabid
carnivor
postexposur
antibodi
prophylaxi
also
proven
invalu
human
medicin
human
rabi
immun
globulin
provid
rapid
protect
given
first
day
postexposur
prophylaxi
regimen
much
possibl
prepar
infiltr
around
wound
may
given
intramuscularli
site
distant
rabi
vaccin
appli
simultan
companion
anim
practic
prevent
activ
immun
commonplac
serum
prophylaxistherapi
consid
except
circumst
eg
dog
present
distemp
cat
present
panleukopenia
diseas
outbreak
kennelcatteri
still
market
serum
immunoglobulin
product
compani
produc
exist
usa
germani
czech
republ
slovakia
russia
brazil
prepar
either
homolog
heterolog
eg
hors
origin
polyval
direct
sever
virus
consist
sera
immunoglobulin
fraction
despit
avail
product
vgg
recommend
use
conserv
care
consider
case
outbreak
cdv
infect
kennel
much
safer
effect
vaccin
dog
cdv
vaccin
rather
give
immun
serum
see
tabl
larson
schultz
situat
previous
recommend
mlv
vaccin
administ
intraven
offlabel
rather
subcutan
intramuscularli
littl
evid
practic
provid
effect
rapid
protect
subcutan
intramuscular
inject
administr
cdv
vaccin
rout
provid
protect
sever
diseas
death
immedi
journal
small
anim
practic
vol
januari
wsava
shortli
vaccin
instanc
vaccin
prevent
infect
instead
protect
sever
diseas
especi
neurolog
diseas
anim
surviv
subsequ
immun
life
case
catteri
outbreak
fpv
infect
kennel
outbreak
infect
recent
studi
shown
immun
plasma
given
clinic
sign
appear
benefit
reduct
morbid
mortal
bragg
et
al
howev
work
criticis
small
volum
ml
immun
plasma
given
puppi
studi
much
larger
volum
mlkg
routin
use
research
practition
larg
dose
believ
experienc
clinician
investig
efficaci
dodd
order
maxim
benefici
effect
immun
serum
plasma
must
given
infect
prior
onset
clinic
sign
case
administr
immun
serum
plasma
best
provid
within
hour
infect
larg
amount
high
titr
serum
plasma
requir
serum
plasma
must
given
parenter
eg
subcutan
intraven
intraperiton
oral
benefit
oral
administr
even
treatment
start
prior
infect
import
consider
shelter
situat
rel
cost
commerci
product
altern
practic
sometim
use
shelter
situat
collect
serum
plasma
anim
shelter
surviv
diseas
recent
vaccin
howev
practic
carri
risk
serum
necessarili
screen
transmiss
pathogen
eg
haemoparasit
felin
retrovirus
serolog
test
provid
effect
approach
control
diseas
outbreak
shelter
situat
see
tabl
sinc
public
wsava
guidelin
newli
introduc
vaccin
includ
bordetella
bronchiseptica
vaccin
oral
administr
hess
et
al
elli
global
increas
rang
leptospira
vaccin
contain
multipl
geograph
relev
serogroup
klaasen
et
al
schuller
et
al
product
describ
tabl
vaccin
canin
influenza
viru
civ
infect
licens
usa
deshpand
et
al
larson
et
al
influenza
subtyp
well
recogn
caus
respiratori
diseas
north
american
dog
hous
togeth
crawford
et
al
payungporn
et
al
castleman
et
al
date
sporad
outbreak
recogn
report
elsewher
crawford
et
al
dali
et
al
kirkland
et
al
pratelli
colao
schulz
et
al
civ
vaccin
contain
inactiv
viru
administ
pup
week
age
second
dose
week
later
annual
revaccin
immun
develop
approxim
day
second
dose
vaccin
consid
noncor
recommend
atrisk
dog
north
america
like
expos
part
lifestyl
anderson
et
al
time
write
local
outbreak
canin
influenza
attribut
viru
subtyp
report
chicago
wisconsin
region
usa
condit
licens
vaccin
subtyp
releas
first
canin
immunotherapeut
vaccin
malign
melanoma
licens
product
compris
human
tyrosinas
gene
incorpor
plasmid
nake
dna
vaccin
repeatedli
deliv
use
highpressur
transderm
inject
devic
vaccin
use
adjunct
treatment
dog
oral
melanoma
induc
immun
respons
melanoma
target
antigen
initi
studi
show
median
surviv
time
dog
grade
iiiv
melanoma
increas
day
expect
surviv
day
bergman
et
al
recent
studi
shown
lesser
effect
grosenbaugh
et
al
ottnod
et
al
vaccin
also
avail
europ
usa
limit
use
recogn
veterinari
oncolog
specialist
two
licens
vaccin
canin
leishmaniosi
recent
avail
brazil
leishmaniosi
diseas
major
import
canin
human
popul
first
subunit
product
contain
leishmania
donovani
also
known
fucos
mannos
ligand
fml
saponin
adjuv
consid
induc
antibodi
block
transmiss
organ
dog
sandfli
vector
prevent
bind
leishmania
midgut
sand
fli
extens
evalu
immunolog
epidemiolog
field
studi
palatnik
de
sousa
et
al
palatnik
de
sousa
day
howev
product
recent
withdrawn
brazilian
market
second
brazilian
vaccin
contain
antigen
l
donovani
saponin
adjuv
vaccin
report
induc
similar
protect
effect
vaccin
dog
ie
respect
seroconvers
prevent
infect
clinic
sign
transmiss
vector
fml
vaccin
compar
natur
exposur
field
trial
endem
area
month
period
dog
vaccin
vaccin
develop
lesser
humor
immun
respons
show
greater
frequenc
advers
event
post
vaccin
fernand
et
al
european
leishmania
vaccin
dog
introduc
bongiorno
et
al
moreno
et
al
vaccin
contain
excretorysecretori
antigen
leishmania
infantum
adjuv
vaccin
use
seroneg
dog
month
age
three
primari
dose
administ
week
apart
annual
booster
vaccin
dog
seroconvert
product
datasheet
describ
discriminatori
serolog
test
evid
cellmedi
immun
respons
also
suggest
vaccin
claim
reduc
likelihood
infect
reduc
sever
clinic
sign
infect
dog
make
public
health
claim
effect
human
diseas
preval
basic
immun
schedul
guidelin
recommend
core
recommend
noncor
option
recommend
vaccin
cat
visit
gener
veterinari
practic
given
tabl
core
vaccin
cat
protect
felin
panleukopenia
fpv
fcv
particular
exampl
vaccin
may
consid
core
countri
rabi
viru
geograph
area
infect
endem
vgg
recommend
cat
routin
vaccin
protect
pet
human
popul
countri
mandatori
rabi
vaccin
legal
requir
although
alway
includ
cat
rabi
vaccin
also
requir
intern
pet
travel
term
felin
core
vaccin
import
realiz
protect
afford
fcv
vaccin
match
immun
provid
fpv
vaccin
thu
felin
core
respiratori
diseas
vaccin
expect
give
robust
protect
durat
immun
seen
canin
core
vaccin
fcv
vaccin
design
produc
crossprotect
immun
multipl
strain
fcv
howev
still
possibl
infect
diseas
occur
vaccin
adult
anim
pedersen
et
al
schorrevan
et
al
vaccin
protect
infect
virul
viru
infect
may
lead
virul
viru
becom
latent
possibl
reactiv
period
sever
stress
richter
et
al
mae
reactiv
viru
may
caus
clinic
sign
vaccin
anim
viru
shed
suscept
anim
caus
diseas
vgg
recommend
triennial
revaccin
lowrisk
cat
fcv
basi
publish
studi
show
minimum
durat
partial
clinic
signific
immun
year
core
vaccin
scott
geissing
recent
studi
mlv
vaccin
seem
show
much
less
substanti
partial
protect
year
post
vaccin
although
fcv
partial
protect
compar
shown
scott
geissing
ja
et
al
vgg
recommend
annual
revaccin
cat
carri
higherrisk
situat
lowrisk
cat
might
defin
solitari
indoor
anim
visit
board
catteri
higherrisk
cat
might
defin
anim
regularli
visit
board
catteri
live
multicat
indooroutdoor
household
moreov
vgg
encourag
practition
consid
time
administr
vaccin
higherrisk
regularli
board
cat
robust
immun
confer
vaccin
occur
within
period
vaccin
gaskel
et
al
administr
vaccin
might
best
time
immedi
regularli
board
cat
due
make
annual
visit
catteri
vaccin
felin
leukaemia
viru
felv
also
often
point
debat
amongst
expert
vgg
regard
felv
noncor
vaccin
tabl
fulli
appreci
use
product
must
determin
lifestyl
perceiv
exposur
risk
individu
cat
preval
infect
local
environ
mani
felin
expert
believ
even
though
preval
felv
infect
markedli
reduc
mani
part
world
due
success
control
programm
weijer
daam
weijer
et
al
meichner
et
al
geograph
area
felv
infect
remain
preval
cat
less
year
old
element
outdoor
lifestyl
eg
even
live
cat
goe
outdoor
receiv
benefit
protect
routin
vaccin
two
dose
vaccin
given
week
apart
start
earlier
week
age
riskbenefit
analysi
felv
form
routin
part
felin
vaccin
interview
felvneg
cat
vaccin
vgg
also
reconsid
fiv
vaccin
previou
iter
guidelin
categor
recommend
basi
categor
question
crossprotect
subtyp
viru
includ
vaccin
subtyp
recombin
field
differ
geograph
area
hosi
et
al
dunham
et
al
yamamoto
et
al
coleman
et
al
beczkowski
et
al
interfer
vaccin
antibodi
test
use
diagnosi
fiv
infect
hosi
beatti
fact
adjuv
vaccin
must
given
repeatedli
primari
cours
three
inject
annual
revaccin
speci
suscept
inject
site
sarcoma
vgg
awar
part
world
remain
signific
preval
fiv
seroposit
andor
infect
bennett
et
al
hosi
et
al
friend
et
al
glennon
et
al
bandecchi
et
al
hitt
et
al
ueland
lutz
jone
et
al
hofmannlehmann
et
al
yilmaz
et
al
lee
et
al
muirden
norri
et
al
gleich
et
al
ravi
et
al
band
et
al
chang
fung
martel
et
al
rypula
et
al
discriminatori
serolog
test
kusuhara
et
al
levi
et
al
westman
et
al
robust
polymeras
chain
reaction
pcr
test
diagnosi
fiv
infect
arjona
et
al
wang
et
al
morton
et
al
mani
countri
unlik
cat
owner
persuad
keep
cat
indoor
away
major
risk
fiv
transmiss
bite
infect
cat
diseas
progress
fivinfect
cat
recent
shown
impact
hous
condit
number
cat
household
beczkowski
et
al
given
vaccin
shown
efficaci
studi
other
might
benefit
atrisk
popul
cat
vgg
reclassifi
product
noncor
vaccin
kitten
vaccin
booster
discuss
puppi
kitten
protect
mda
first
week
life
howev
without
serolog
test
level
protect
point
kitten
becom
suscept
infect
respond
immunolog
vaccin
unknown
relat
level
matern
antibodi
variat
uptak
mda
litter
individu
gener
mda
wane
week
age
level
allow
activ
immunolog
respons
howev
kitten
poor
mda
may
vulner
capabl
respond
vaccin
earlier
age
other
may
possess
mda
high
titr
incap
respond
vaccin
sometim
week
age
vgg
review
recent
studi
suggest
one
third
kitten
may
fail
respond
final
core
vaccin
given
week
age
proport
kitten
may
still
block
mda
week
age
digangi
et
al
jakel
et
al
vgg
note
one
studi
rel
low
number
anim
domin
one
breed
within
catteri
set
suggest
data
may
fulli
applic
wider
felin
popul
nevertheless
vgg
increas
recommend
age
final
vaccin
seri
primari
core
vaccin
week
age
week
older
vgg
recommend
core
vaccin
kitten
therefor
line
schedul
propos
puppi
begin
week
age
repeat
vaccin
everi
week
week
age
older
therefor
number
kitten
primari
core
vaccin
determin
age
vaccin
start
chosen
revaccin
interv
possibl
schedul
outlin
tabl
recommend
vaccin
start
week
age
cours
four
primari
core
vaccin
would
administ
three
would
requir
start
integr
part
core
vaccin
kitten
booster
vaccin
tradit
given
either
month
age
month
last
primari
seri
kitten
vaccin
main
aim
vaccin
ensur
protect
immun
respons
develop
cat
may
fail
respond
three
vaccin
primari
core
seri
rather
necessarili
boost
immun
respons
deliveri
vaccin
month
age
like
chosen
histor
conveni
time
request
owner
attend
practic
first
annual
health
check
therefor
impli
individu
kitten
fail
respond
three
primari
core
vaccin
kitten
may
unprotect
receiv
vaccin
might
account
occurr
infecti
diseas
proport
vaccin
kitten
less
month
age
vgg
reevalu
practic
suggest
veterinarian
might
wish
reduc
possibl
window
suscept
bring
forward
vaccin
week
week
age
inde
time
point
week
age
howev
week
age
provid
conveni
time
practic
requir
pet
owner
clearli
understand
recommend
indic
tabl
adopt
protocol
mean
vaccin
start
week
old
kitten
might
entail
five
vaccin
visit
first
month
life
core
vaccin
week
booster
anoth
core
vaccin
would
requir
least
anoth
year
lowrisk
cat
puppi
adopt
week
vaccin
approach
would
preclud
first
annual
health
check
month
age
cat
respond
vaccin
mlv
core
vaccin
maintain
solid
immun
immunolog
memori
fpv
mani
year
absenc
repeat
vaccin
immun
fcv
partial
geissing
ja
et
al
vgg
recommend
adult
lowrisk
cat
revaccin
mlv
core
vaccin
interv
year
longer
higherrisk
cat
see
definit
veterinarian
might
consid
administ
fpv
vaccin
frequent
everi
year
give
fcv
vaccin
annual
latter
product
time
administr
shortli
regular
annual
visit
board
catteri
recommend
gener
appli
kill
core
vaccin
except
rabi
noncor
vaccin
particularli
vaccin
contain
bacteri
antigen
thu
chlamydia
formerli
chlamydophila
sachs
et
al
bordetella
product
use
deem
necessari
requir
annual
booster
limit
protect
afford
product
therefor
accord
guidelin
adult
cat
may
still
receiv
annual
vaccin
howev
compon
vaccin
may
differ
year
year
typic
core
vaccin
especi
fpv
current
administ
triennial
respiratori
viru
vaccin
given
accord
risk
chosen
noncor
product
given
annual
vgg
awar
countri
multicompon
product
contain
core
noncor
combin
avail
vgg
would
encourag
manufactur
make
full
rang
vaccin
avail
wherev
possibl
least
make
coreonli
combin
want
give
noncor
vaccin
adult
cat
receiv
complet
cours
vaccin
fpv
fcv
kitten
includ
booster
may
regularli
vaccin
adult
requir
singl
dose
mlv
core
vaccin
boost
immun
adopt
adult
cat
kitten
week
age
unknown
vaccin
histori
requir
singl
dose
mlv
fpv
core
vaccin
engend
protect
immun
respons
viru
contrast
adopt
adult
cat
unknown
vaccin
histori
receiv
two
dose
mlv
vaccin
week
apart
establish
adequ
immun
respons
vaccin
type
one
class
inject
product
link
pathogenesi
felin
inject
site
sarcoma
fiss
particular
attent
focus
administr
adjuv
felv
rabi
vaccin
kass
et
al
fiss
subject
much
research
number
recent
review
subject
martano
et
al
srivastav
et
al
ladlow
although
pathogenesi
fiss
remain
unproven
current
belief
local
chronic
inflammatori
reaction
initi
malign
transform
mesenchym
cell
process
genet
basi
subcutan
inject
includ
vaccin
tradit
given
interscapular
region
cat
remain
common
site
format
fiss
infiltr
natur
tumour
mean
radic
surgic
resect
often
necessari
attempt
remov
lesion
although
adjunct
treatment
modal
also
use
martano
et
al
ladlow
north
america
respons
issu
recommend
protocol
wherebi
two
perceiv
highrisk
adjuv
vaccin
would
administ
distinct
anatom
site
would
amen
surgic
remov
fiss
might
develop
accordingli
recommend
left
leg
leukaemia
right
leg
rabi
suggest
felv
vaccin
given
far
distal
possibl
left
hindlimb
whilst
rabi
vaccin
given
far
distal
possibl
right
hindlimb
recommend
remain
current
aafp
guidelin
scherk
et
al
also
specifi
administr
three
felin
core
vaccin
distal
forelimb
one
studi
evalu
effect
practic
compar
anatom
distribut
fiss
cat
recommend
made
practic
adopt
shaw
et
al
data
show
signific
decreas
preval
interscapular
fiss
increas
preval
tumour
right
left
forelimb
notabl
also
increas
number
tumour
report
aris
combin
region
right
hindlimb
right
later
aspect
abdomen
left
hindlimb
left
later
aspect
abdomen
attribut
difficultli
inject
distal
hindlimb
abdomin
site
accident
inject
practic
wide
adopt
outsid
north
america
recent
one
public
shown
efficaci
administ
fpv
rabi
vaccin
tail
cat
hendrick
et
al
adult
cat
commun
trapneuterreturn
programm
given
trival
mlv
core
vaccin
fpv
fcv
distal
third
dorsal
tail
inactiv
rabi
vaccin
administ
cm
distal
site
trival
vaccin
seroconvers
occur
cat
fpv
one
cat
rabi
viru
tail
vaccin
report
well
toler
cat
small
studi
wsava
vaccin
guidelin
vgg
propos
altern
deliv
vaccin
skin
later
thorax
better
later
abdomen
day
et
al
tail
inject
may
prove
safer
altern
distal
limb
inject
later
bodi
wall
inject
studi
tail
vaccin
requir
remain
confus
contenti
area
individu
practition
must
decid
approach
practic
practic
set
howev
follow
principl
still
appli
risk
fiss
outweigh
benefit
protect
immun
confer
vaccin
current
estim
preval
fiss
everi
cat
vaccin
gobar
kass
dean
et
al
nonadjuv
vaccin
administ
cat
wherev
possibl
vaccin
particularli
adjuv
product
inject
administ
interscapular
region
vaccin
particularli
adjuv
product
administ
subcutan
intramuscular
site
choic
site
base
balanc
eas
surgic
resect
fiss
might
develop
accept
safeti
vaccin
ie
avoid
accident
selfinject
difficult
restraint
anim
vaccin
administ
differ
site
occas
site
record
patient
record
vaccin
card
use
diagram
indic
product
administ
one
occas
site
rotat
occas
altern
practic
might
develop
group
polici
felin
vaccin
administ
specif
site
one
calendar
year
site
rotat
follow
year
vgg
encourag
case
suspect
fiss
notifi
via
appropri
nation
report
rout
suspect
advers
reaction
vaccin
manufactur
sinc
public
guidelin
one
commerci
inpractic
rapid
test
determin
serum
antibodi
fpv
fcv
becom
avail
test
valid
appli
seri
publish
investig
mend
et
al
test
kit
may
use
determin
presenc
protect
antibodi
fpv
excel
correl
presenc
antibodi
resist
infect
lappin
et
al
fpv
test
kit
report
specif
sensit
mend
et
al
correl
circul
serum
antibodi
protect
fcv
infect
less
robust
presenc
adequ
local
mucos
immun
cellmedi
immun
respect
reason
neg
test
result
fcv
antibodi
would
necessarili
indic
lack
protect
particular
cat
lappin
et
al
test
appli
practic
describ
dog
determin
protect
kitten
follow
fpv
vaccin
determin
protect
fpv
adult
cat
order
inform
decis
revaccin
use
shelter
situat
control
outbreak
fpv
infect
emphas
antibodi
test
fiv
use
diagnos
diseas
valu
determin
immun
fiv
discuss
fiv
vaccin
use
fiv
infect
suspect
diagnosi
made
use
discriminatori
serolog
test
prefer
valid
pcr
test
anim
shelter
hold
facil
anim
usual
await
adopt
rescu
reclam
owner
gener
anim
shelter
character
random
sourc
popul
mostli
unknown
vaccin
histori
high
popul
turnov
high
infecti
diseas
risk
term
shelter
encompass
situat
rang
sanctuari
possess
stabl
popul
facil
admit
hundr
anim
per
day
rescu
foster
home
care
multipl
individu
litter
given
time
vaccin
strategi
vari
individu
pet
onesizefitsal
strategi
vaccin
shelter
anim
likelihood
exposur
potenti
devast
consequ
infect
necessit
clearli
defin
shelter
vaccin
program
shelter
medicin
differ
individu
care
clinician
practic
environ
erad
infecti
diseas
attain
possibl
howev
minim
spread
infect
within
highdens
highrisk
popul
maintain
health
notyetinfect
individu
overal
purpos
place
healthi
pet
welcom
home
time
effort
dedic
control
infecti
diseas
one
mani
variabl
complex
shelter
medicin
husbandri
equat
recommend
provid
attempt
address
shelteruniqu
issu
pertain
vaccin
diseas
control
guidelin
recommend
vaccin
use
shelter
given
tabl
updat
guidelin
standard
recommend
puppi
kitten
enter
shelter
indic
core
vaccin
may
start
earli
week
age
fund
permit
revaccin
everi
week
anim
reach
week
age
remain
shelter
time
recent
us
studi
shown
cat
enter
shelter
may
seroposit
vaccineprevent
infecti
diseas
agent
digangi
et
al
report
seroposit
fpv
fcv
fischer
et
al
report
seroposit
fpv
fcv
rabi
viru
seroposit
cdv
less
cpv
dog
enter
one
us
shelter
litster
et
al
anoth
studi
dog
seroposit
cdv
cpv
cdv
cpv
neither
viru
lechner
et
al
unambigu
document
vaccin
provid
adult
anim
time
admiss
shelter
reason
revaccin
canin
core
vaccin
felin
core
vaccin
specif
fcv
may
valu
boost
immun
vgg
discrimin
shelter
board
kennelcatteri
latter
facil
fulli
vaccin
anim
may
temporarili
board
rel
short
period
time
eg
owner
vacat
requir
entri
facil
individu
dog
cat
fulli
vaccin
core
product
given
accord
guidelin
present
herein
dog
use
noncor
vaccin
respiratori
infect
also
appropri
circumst
vgg
awar
countri
vaccin
protocol
anim
enter
board
kennelcatteri
formul
local
author
may
contrari
current
guidelin
eg
insist
annual
revaccin
vgg
encourag
author
reconsid
recommend
light
current
scientif
think
product
avail
encourag
veterinari
profess
nation
associ
lobbi
chang
sinc
public
guidelin
avail
rapid
inhous
serolog
test
kit
major
impact
manag
outbreak
cdv
cpv
fpv
anim
shelter
approach
use
kit
situat
outlin
tabl
past
veterinari
practic
benefit
annual
administr
vaccin
encourag
owner
bring
pet
yearli
vaccin
veterinarian
abl
recogn
treat
diseas
earlier
might
otherwis
case
addit
annual
visit
provid
opportun
inform
client
import
aspect
canin
felin
health
care
unfortun
mani
client
come
believ
vaccin
import
reason
annual
veterinari
visit
veterinarian
concern
reduct
vaccin
frequenc
caus
client
forgo
annual
visit
journal
small
anim
practic
vol
januari
wsava
qualiti
care
diminish
therefor
essenti
veterinarian
stress
import
aspect
comprehens
individu
health
care
program
emphasi
place
detail
histori
take
thorough
physic
examin
perform
presenc
client
individu
patient
care
import
dental
care
proper
nutrit
appropri
diagnost
test
control
parasit
zoonot
diseas
address
evalu
pet
behaviour
concern
discuss
well
necess
frequent
tailor
examin
young
geriatr
anim
anim
particular
breed
well
character
diseas
predisposit
discuss
vaccin
simpli
one
part
annual
health
check
visit
regular
usual
annual
health
check
clinician
assess
need
core
noncor
vaccin
particular
year
practition
explain
client
type
vaccin
avail
potenti
benefit
risk
applic
particular
anim
given
lifestyl
risk
exposur
anim
might
receiv
core
vaccin
everi
year
noncor
vaccin
requir
annual
administr
owner
continu
see
anim
vaccin
annual
region
incid
risk
factor
variou
infecti
diseas
also
discuss
way
reduc
impact
acquir
diseas
eg
avoid
overcrowd
improv
nutrit
restrict
access
infect
anim
also
review
vaccin
consid
one
compon
comprehens
prevent
health
care
plan
individu
base
age
breed
health
statu
environ
potenti
exposur
harm
agent
lifestyl
contact
anim
travel
habit
pet
age
signific
effect
prevent
health
care
need
given
individu
puppykitten
program
tradit
focus
vaccin
parasit
control
neuter
today
opportun
exist
incorpor
behaviour
counsel
zoonot
diseas
manag
age
pet
senior
care
program
becom
increasingli
popular
nutrit
dental
diseas
parasit
control
assess
counsel
take
place
individu
basi
throughout
life
pet
evid
older
dog
cat
fulli
vaccin
pup
kitten
requir
special
programm
core
vaccin
day
horzinek
experiment
evid
show
older
dog
cat
persist
immunolog
memori
core
vaccin
detect
measur
serum
antibodi
may
readili
boost
administr
singl
vaccin
dose
day
adult
anim
decis
revaccin
core
product
cdv
cav
cpv
fpv
may
made
via
serolog
test
practition
offer
altern
vaccin
report
greatli
appreci
owner
may
concern
vaccin
frequenc
offer
altern
act
practic
builder
contrast
age
anim
may
effici
mount
primari
immun
respons
novel
antigen
previous
encount
day
studi
uk
dog
cat
vaccin
first
time
rabi
pet
travel
clearli
shown
age
anim
fail
achiev
legal
requir
antibodi
titr
kennedi
et
al
environ
pet
resid
profoundli
affect
health
statu
assess
annual
health
care
visit
order
defin
risk
factor
develop
appropri
prevent
measur
estim
extent
dog
cat
come
contact
anim
unobserv
circumst
veterinarian
assess
need
noncor
vaccin
dog
visit
kennel
groom
salon
common
area
wood
tickinfest
area
potenti
greater
risk
certain
infecti
diseas
dog
frequent
area
human
popul
becom
mobil
pet
popul
result
potenti
exposur
infecti
agent
parasit
environment
hazard
found
anim
normal
live
determin
past
anticip
futur
travel
visit
allow
greater
individu
prevent
care
diagnost
test
plan
time
vaccin
administr
follow
inform
record
patient
perman
medic
record
date
vaccin
administr
ident
name
initi
code
person
administ
vaccin
vaccin
name
lot
serial
number
expiri
date
manufactur
site
rout
vaccin
administr
use
peeloff
vaccin
label
stamp
imprint
medic
record
outlin
pet
facilit
type
record
keep
mandatori
countri
advers
event
record
manner
alert
staff
member
futur
visit
inform
consent
document
medic
record
order
demonstr
relev
inform
provid
client
client
author
procedur
eg
offlabel
use
product
discuss
least
notat
indic
discuss
risk
benefit
took
place
prior
vaccin
vgg
recommend
vaccin
certif
design
includ
date
vaccin
administ
also
field
veterinarian
state
date
vaccin
next
recommend
help
diminish
confus
mind
pet
owner
kennelcatteri
proprietor
annual
often
highrisk
anim
protect
annual
booster
noncor
b
bronchiseptica
avail
singl
product
combin
cpiv
cpiv
transient
day
cough
sneez
nasal
discharg
may
occur
small
percentag
vaccin
intranas
oral
vaccin
must
deliv
parenter
inject
may
lead
sever
advers
reaction
includ
death
bordetella
bronchiseptica
kill
bacterin
parenter
bordetella
bronchiseptica
cell
wall
antigen
extract
parenter
administ
one
dose
week
one
dose
week
age
two
dose
week
apart
annual
often
highrisk
anim
protect
annual
booster
noncor
intranas
oral
product
prefer
kill
parenter
provid
local
protect
howev
review
publish
time
compil
question
advantag
elli
australia
monoval
vaccin
contain
serogroup
australi
new
zealand
monoval
serogroup
icterohaemorrhagia
vaccin
avail
initi
dose
week
age
older
second
dose
given
week
later
two
dose
week
apart
annual
noncor
leptospira
vaccin
develop
account
known
circul
pathogen
serogroup
differ
geograph
area
note
leptospira
serogroup
may
includ
multipl
serovar
often
confus
use
term
serogroup
serovar
vaccin
restrict
use
geograph
area
risk
exposur
establish
dog
whose
lifestyl
place
risk
vaccin
known
provid
protect
less
robust
may
shorter
durat
therefor
product
must
administ
annual
past
leptospira
bacterin
vaccin
suggest
link
higher
preval
allerg
advers
event
particularli
small
breed
dog
administ
one
dose
time
admiss
week
age
second
dose
week
later
two
dose
week
apart
recommend
parenter
vaccin
recommend
possibl
administ
intranas
oral
vaccin
canin
respiratori
diseas
complex
kennel
cough
vaccineprevent
diseas
vaccin
use
help
manag
diseas
singl
dose
administ
time
discharg
facil
singl
dose
administ
time
discharg
facil
administr
rabi
vaccin
determin
whether
shelter
countri
diseas
endem
local
statut
usa
civ
vaccin
often
use
shelter
situat
two
dose
given
week
apart
mani
recommend
shelter
differ
use
vaccin
own
pet
dog
practic
situat
recommend
take
account
potenti
high
infecti
diseas
pressur
shelter
environ
journal
small
anim
practic
vol
januari
wsava
mlv
prepar
prefer
use
intranas
fpv
vaccin
recommend
shelter
environ
schultz
use
intranas
mlv
vaccin
may
prefer
rapid
onset
hr
immun
import
postvaccin
sneez
commonli
seen
follow
administr
intranas
vaccin
imposs
distinguish
activ
infect
singl
dose
administ
time
discharg
facil
singl
dose
administ
time
discharg
facil
administr
rabi
vaccin
determin
whether
shelter
countri
diseas
endem
vaccin
requir
law
vgg
recommend
use
felin
vaccin
shelter
situat
provid
exampl
possibl
vaccin
schedul
puppi
kitten
vaccin
given
either
everi
week
would
normal
done
veterinari
practic
own
pet
anim
although
revaccin
everi
week
might
use
area
high
infecti
diseas
pressur
geograph
area
protocol
shown
simplic
present
week
booster
vaccin
vaccin
core
product
frequent
everi
year
except
felin
respiratori
viru
vaccin
higher
risk
cat
vaccin
optimum
storag
temperatur
usual
domest
refriger
maintain
product
frozen
posit
adjac
freezer
compart
refriger
refriger
temperatur
monitor
regularli
vaccin
transport
field
also
subject
continu
cold
chain
freezedri
vaccin
reconstitut
immedi
use
appropri
diluent
liquid
vaccin
given
simultan
per
manufactur
recommend
bad
practic
contraind
make
vaccin
anticip
use
day
first
thing
morn
vaccin
compon
eg
cdv
particularli
labil
regard
vaccin
may
induc
adequ
immun
reconstitut
use
vaccin
mix
togeth
syring
specifi
accept
manufactur
data
sheet
syring
needl
vaccin
reutil
vaccin
inject
site
steril
alcohol
disinfect
may
inactiv
infecti
mlv
vaccin
vaccin
date
precis
detail
batch
number
compon
site
inject
note
anim
medic
record
day
schultz
seroposit
anim
protect
becom
infect
die
separ
nonor
lowrespond
anim
seroneg
anim
separ
seroposit
anim
anim
suscept
adopt
shelter
incub
period
infect
ie
least
week
cpv
least
week
cdv
anim
vaccin
retest
confirm
seroposit
incub
period
anim
outsid
shelter
need
admit
face
diseas
outbreak
shelter
seroposit
anim
may
safe
enter
shelter
protect
diseas
anim
vaccin
sent
foster
home
seroconvert
allow
enter
shelter
seroposit
advers
event
defin
side
effect
unintend
consequ
includ
lack
protect
associ
administr
vaccin
product
includ
injuri
toxic
hypersensit
reaction
associ
vaccin
whether
event
directli
attribut
vaccin
advers
event
report
whether
associ
vaccin
recogn
suspect
vaccin
advers
event
report
identifi
product
anim
involv
event
individu
submit
report
report
field
observ
unexpect
vaccin
perform
import
mean
manufactur
regulatori
agenc
alert
potenti
vaccin
safeti
efficaci
problem
may
warrant
investig
purpos
prelicensur
safeti
studi
detect
rel
common
advers
event
rare
delay
advers
event
detect
postmarket
surveil
analysi
report
advers
event
advers
event
report
manufactur
andor
local
regulatori
author
mani
countri
government
surveil
scheme
avail
reaction
therefor
notifi
manufactur
vgg
recogn
gross
underreport
vaccineassoci
advers
event
passiv
natur
report
scheme
imped
knowledg
ongo
safeti
product
vgg
would
activ
encourag
veterinarian
particip
surveil
scheme
particular
advers
event
well
document
report
serv
provid
baselin
futur
report
compar
addit
report
advers
event
lead
detect
previous
unrecogn
reaction
detect
increas
known
reaction
recognit
risk
factor
associ
reaction
identif
vaccin
lot
unusu
event
higher
number
advers
event
stimul
clinic
epidemiolog
laboratori
studi
therefor
veterinarian
encourag
report
clinic
signific
advers
event
occur
administr
licens
vaccin
report
vaccin
advers
event
indict
particular
vaccin
facilit
review
tempor
associ
condit
add
safeti
databas
product
work
vaccin
guidelin
group
gener
sponsor
msd
anim
health
wsava
vgg
independ
group
academ
expert
formul
guidelin
without
consult
industri
repres
sponsor
compani
attend
vgg
meet
compani
right
veto
vgg
recommend
vgg
acknowledg
import
work
undertaken
american
anim
hospit
associ
aaha
canin
vaccin
task
forc
american
associ
felin
practition
aafp
felin
vaccin
advisori
panel
develop
recommend
vaccin
dog
cat
respect
north
america
vgg
also
acknowledg
work
european
advisori
board
cat
diseas
abcd
formul
recommend
felin
vaccin
european
perspect
appendic
fact
sheet
canin
parvoviru
type
vaccin
type
vaccin
avail
modifi
live
viru
mlv
vaccin
three
contemporari
variant
refer
origin
variant
rare
isol
nowaday
although
still
present
modifi
live
vaccin
shed
vaccin
recipi
recent
variant
emerg
genotyp
recogn
north
south
america
europ
africa
asia
ohneis
et
al
genotyp
antigen
relat
challeng
studi
shown
vaccin
dog
current
cpv
vaccin
contain
either
provid
protect
immun
variant
includ
spibey
et
al
decaro
buonavoglia
convers
one
report
outbreak
infect
vaccin
adult
dog
decaro
et
al
dog
vaccin
day
age
adult
receiv
annual
booster
inactiv
kill
vaccin
kill
vaccin
avail
less
effect
take
much
longer
induc
immun
respons
compar
mlv
vaccin
pollock
carmichael
recommend
routin
use
kill
vaccin
may
provid
benefit
wild
exot
speci
pregnant
bitch
mlv
vaccin
recommend
howev
kill
vaccin
test
safeti
efficaci
situat
doi
natur
infectiondiseas
thought
lifelong
major
dog
doi
vaccin
mlv
vaccin
year
longer
base
challeng
serolog
studi
doi
vaccin
kill
vaccin
year
longer
mda
interfer
activ
immun
vari
period
time
puppi
depend
titr
colostr
antibodi
amount
antibodi
absorb
birth
well
specif
vaccin
pollock
carmichael
window
suscept
defin
period
time
pup
infect
field
viru
vaccin
immun
highli
effect
mlv
vaccin
ie
high
titr
low
passag
window
suscept
short
week
less
less
effect
mlv
vaccin
window
suscept
long
week
schultz
larson
hoar
et
al
complet
puppi
seri
week
older
vaccin
month
age
revaccin
need
done
often
everi
year
absenc
mda
mlv
vaccin
provid
immun
earli
day
vaccin
schultz
larson
presenc
serum
antibodi
regardless
titr
activ
immun
dog
age
week
correl
protect
mlv
vaccin
use
wildlif
speci
mlv
vaccin
use
pregnant
bitch
unless
specif
indic
puppi
younger
week
age
vaccin
mlv
product
infect
take
day
sign
diseas
appear
faecal
shed
rare
persist
week
dog
persist
infect
week
report
one
expect
anim
die
clear
viru
period
time
environ
viru
remain
infecti
year
therefor
facil
infect
anim
present
must
consid
infect
tori
diseas
associ
infect
except
effect
caus
advers
reaction
commonli
seen
vaccin
known
allerg
uveiti
blue
eye
curti
barnett
addit
parenter
mlv
vaccin
prepar
combin
monoval
product
protect
canin
infecti
respiratori
diseas
complex
cirdc
includ
bordetella
bronchiseptica
canin
parainfluenza
viru
cpiv
intranas
product
contain
cpiv
bordetella
use
decreas
sever
cirdc
use
vaccin
prevent
ich
purpos
parenter
also
given
inactiv
kill
vaccin
inactiv
kill
vaccin
sold
countri
recommend
mlv
product
avail
less
effect
doi
naturallyacquir
canin
infecti
hepat
thought
lifelong
major
dog
doi
vaccin
mlv
vaccin
year
longer
major
dog
base
challeng
serolog
studi
doi
protect
ich
kill
vaccin
like
shorter
mlv
product
mda
block
immun
vaccin
parenter
product
last
dose
given
along
core
viral
vaccin
eg
cdv
puppi
week
age
older
complet
puppi
seri
week
older
vaccin
week
age
revaccin
need
done
often
everi
year
absenc
mda
mlv
vaccin
protect
ich
earli
day
vaccin
presenc
serum
antibodi
regardless
titr
activ
immun
dog
age
week
correl
protect
intranas
vaccin
intend
aid
prevent
upper
respiratori
diseas
caus
intend
protect
infect
transmit
primarili
contamin
secretionsexcret
saliva
urin
moder
stabl
surviv
sever
day
week
environ
experiment
infect
take
day
longer
sign
ich
appear
window
suscept
defin
period
time
puppi
infect
field
viru
vaccin
immun
unlik
vaccin
gener
prolong
window
vaccin
ie
week
transmit
primarili
air
cirdc
complex
pathogenesi
involv
stress
poor
ventil
dust
ammonia
ga
unsanitari
facil
infect
streptococcu
spp
bordetella
bronchiseptica
mycoplasma
spp
cpiv
civ
canin
pneumoviru
canin
respiratori
coronaviru
combin
agent
associ
cirdc
caus
respiratori
diseas
day
multifactori
diseas
cirdc
vaccineprevent
current
vaccin
help
reduc
diseas
sever
common
product
gener
contain
cdv
strain
rockborn
snyder
hill
onderstepoort
lederl
other
variou
titr
mani
pathotyp
cdv
kapil
et
al
espin
et
al
caus
vari
clinic
sign
wide
varieti
speci
howev
serolog
differ
among
mani
isol
insignific
vaccin
one
current
vaccin
provid
protect
immun
pathotyp
mlv
vaccin
must
use
wildlif
speci
unless
specif
evid
show
safe
vector
recombin
rcdv
vaccin
canarypox
viru
recombin
product
avail
usa
countri
specif
canarypox
vector
recombin
product
also
use
wildlif
exot
speci
connolli
et
al
mlv
prepar
attenu
modifi
safe
use
domest
dog
use
wild
exot
speci
vaccin
highli
virul
eg
blackfoot
ferret
grey
fox
caus
diseas
death
carpent
et
al
pearson
durchfeld
et
al
vaccin
speci
mlv
vaccin
perform
unless
evid
support
safeti
specif
product
puppi
younger
week
age
vaccin
mlv
vaccin
sign
diseas
appear
week
infect
incub
period
cdv
caus
immunosuppress
make
anim
suscept
microbi
infect
secondari
infect
may
lead
respiratori
diseas
pneumonia
death
typic
sign
distemp
viru
infect
appear
environ
viru
quickli
lose
infect
modifi
live
viru
mlv
vaccin
prepar
contain
attenu
avirul
felin
parvoviru
felin
panleukopenia
viru
variou
titr
without
adjuv
inject
prepar
other
intranas
applic
combin
vaccin
antigen
eg
fcv
mlv
vaccin
advantag
faster
onset
action
greater
efficaci
overcom
matern
antibodi
greater
likelihood
confer
suffici
immun
lappin
intranas
fpv
combin
vaccin
use
shelter
environ
use
immun
given
simultan
mlvfpv
parenter
product
schultz
inactiv
kill
vaccin
kill
adjuv
fpv
vaccin
avail
singl
inject
dose
product
may
induc
good
antibodi
respons
cat
within
rel
short
time
span
howev
kill
fpv
product
requir
two
dose
week
apart
immun
present
second
dose
kill
vaccin
may
benefici
wild
exot
speci
pregnant
queen
retrovirallyinfect
cat
mlv
vaccin
recommend
doi
natur
infectiondiseas
lifelong
doi
vaccin
mlv
vaccin
year
longer
base
challeng
serolog
studi
doi
vaccin
kill
panleukopenia
vaccin
demonstr
last
minimum
year
scott
geissing
case
felin
panleukopenia
caus
infect
fpv
variant
canin
parvoviru
emerg
infect
cat
may
caus
diseas
decaro
buonavoglia
certain
current
fpv
vaccin
afford
protect
cpv
variant
matern
deriv
antibodi
mda
interfer
activ
immun
vari
period
time
kitten
depend
titr
colostr
antibodi
amount
antibodi
absorb
first
hour
birth
window
suscept
defin
period
time
kitten
infect
field
viru
vaccin
immun
analog
canin
parvoviru
immun
gap
assum
exist
antibodi
level
low
protect
natur
infect
still
high
enough
interfer
vaccin
journal
small
anim
practic
vol
januari
wsava
complet
kitten
seri
week
older
vaccin
week
age
revaccin
need
done
often
everi
year
presenc
serum
antibodi
regardless
titr
activ
immun
cat
age
week
correl
protect
vaccin
use
control
diseas
face
outbreak
shelter
situat
rapid
induct
immun
induc
mlv
vaccin
clinic
advantag
earli
onset
protect
vaccin
mlv
product
brun
chappui
mlv
fpv
vaccin
use
wild
anim
speci
unless
evid
show
safe
mlv
fpv
vaccin
never
use
pregnant
queen
risk
transfer
viru
fetu
fetal
damag
countri
inactiv
fpv
vaccin
licens
use
pregnant
queen
gener
unnecessari
administr
product
pregnant
queen
avoid
mlv
fpv
vaccin
never
administ
kitten
less
week
age
avoid
damag
cerebellum
still
develop
neonat
mlv
fpv
vaccin
use
sever
immunosuppress
individu
although
risk
appear
small
sever
immunosuppress
exampl
clinic
fiv
felv
infect
use
highli
immunosuppress
drug
failur
control
viral
replic
could
potenti
lead
clinic
sign
vaccin
infect
take
day
sign
diseas
appear
vomit
usual
develop
day
onset
fever
diarrhoea
may
begin
later
alway
present
dehydr
develop
rapidli
affect
cat
may
sit
water
bowl
obvious
thirsti
without
drink
termin
case
hypotherm
may
develop
septic
shock
dissemin
intravascular
coagul
environ
viru
remain
infecti
year
gordon
angrick
facil
infect
anim
present
must
consid
contamin
mechan
durat
immun
doi
protect
afford
well
fcv
vaccin
complet
seen
fpv
vaccin
two
felin
core
vaccin
fcv
expect
provid
robust
degre
durat
immun
seen
canin
core
vaccin
fpv
assess
doi
difficult
complet
clinic
protect
seen
shortli
vaccin
degre
protect
decreas
time
gaskel
et
al
immun
far
solid
natur
infectiondiseas
variabl
durat
persist
antibodi
titr
vaccin
kill
vaccin
demonstr
year
scott
geissing
antibodi
titr
correl
well
protect
gaskel
et
al
protect
challeng
virul
year
vaccin
two
dose
kill
vaccin
complet
similar
protect
year
kill
product
scott
geissing
complet
kitten
seri
week
older
vaccin
week
age
revaccin
need
done
often
everi
year
cat
low
risk
howev
cat
higher
risk
eg
regularli
attend
board
catteri
revaccin
frequent
booster
vaccin
laps
previous
wellvaccin
cat
singl
inject
consid
adequ
boost
immunolog
memori
herpesviru
vaccin
protect
infect
virul
viru
becom
latent
may
reactiv
period
sever
stress
reactiv
viru
may
caus
clinic
sign
vaccin
anim
gaskel
et
al
viru
may
shed
transmit
suscept
anim
caus
diseas
suscept
kitten
cat
gaskel
et
al
cellmedi
immun
play
import
role
protect
sinc
absenc
detect
serum
antibodi
level
vaccin
cat
necessarili
indic
cat
suscept
diseas
mda
interfer
activ
immun
vari
period
time
kitten
depend
titr
colostr
antibodi
amount
antibodi
absorb
birth
primari
cours
vaccin
usual
start
around
week
age
mda
interfer
less
mlv
intranas
vaccin
parenter
administ
mlv
product
would
expect
vaccin
immun
earlier
parenter
vaccin
kitten
mda
breed
catteri
infect
mostli
appear
kitten
prior
wean
typic
week
age
mda
wane
case
sourc
infect
queen
whose
latent
viru
reactiv
due
stress
parturit
lactat
modifi
live
parenter
fcv
vaccin
retain
pathogen
potenti
may
induc
diseas
administ
incorrectli
ie
accident
aerosol
ingest
inhal
vaccin
deposit
skinhair
upper
respiratori
diseas
sign
sometim
seen
follow
intranas
vaccin
viral
excret
start
soon
hour
infect
last
week
acut
diseas
appear
day
resolv
within
day
viru
spread
along
sensori
nerv
reach
neuron
cell
bodi
particularli
trigemin
ganglia
main
site
latenc
cat
becom
lifelong
latent
carrier
shed
viru
period
upon
stress
event
gaskel
et
al
contrast
shed
fcv
continu
period
month
infect
herpesviru
genom
dna
persist
nucleu
infect
neuron
without
replic
environ
viru
labil
inactiv
commonli
use
disinfect
consider
antigen
variabl
amongst
fcv
strain
prior
infect
one
strain
significantli
reduc
acut
clinic
sign
upon
exposur
heterolog
strain
also
oral
viru
shed
gener
level
heterolog
protect
depend
pair
viru
strain
examin
viru
neutral
antibodi
first
appear
approxim
day
infect
titr
correl
well
protect
homolog
challeng
cat
may
also
protect
absenc
serum
antibodi
sinc
local
secretori
iga
antibodi
cellular
respons
demonstr
provid
protect
vaccin
cat
vaccin
kill
adjuv
fcv
vaccin
antibodi
shown
persist
least
year
scott
geissing
protect
challeng
virul
fcv
year
vaccin
two
dose
kill
adjuv
vaccin
incomplet
similar
protect
year
kill
product
scott
geissing
protect
afford
fcv
well
vaccin
complet
seen
fpv
vaccin
two
core
respiratori
vaccin
expect
provid
robust
degre
durat
immun
seen
fpv
canin
core
vaccin
reinfect
fcv
differ
strain
possibl
vaccin
cat
complet
kitten
seri
week
older
vaccin
week
age
revaccin
need
done
often
everi
year
cat
low
risk
howev
cat
higher
risk
eg
regularli
attend
board
catteri
may
revaccin
frequent
recommend
vaccin
contain
viru
strain
use
kitten
seri
mda
import
protect
first
week
life
may
interfer
vaccin
averag
halflif
mda
determin
day
persist
week
johnson
povey
field
studi
kitten
week
age
detect
antibodi
wide
use
vaccin
strain
dawson
et
al
mda
interfer
less
mlv
given
intranas
parenter
administ
mlv
product
would
expect
vaccin
immun
earlier
parenter
vaccin
kitten
mda
upper
respiratori
diseas
sign
may
seen
occasion
complic
intranas
vaccin
lappin
et
al
lappin
et
al
multitud
antigen
differ
virus
circul
field
vaccin
strain
combin
chosen
crossprotect
sever
clinic
diseas
mild
diseas
may
still
occur
vaccin
cat
contrast
shed
intermitt
stress
event
shed
fcv
continu
usual
ceas
sever
month
coyn
et
al
impact
vaccin
shed
controversi
observ
rang
moder
reduct
extens
period
viru
shed
post
infect
live
parenter
fcv
vaccin
strain
shed
although
infrequ
fcv
infect
caus
acut
oral
upper
respiratori
sign
also
associ
chronic
gingivostomat
may
immunemedi
incub
period
day
oral
ulcer
particularli
margin
tongu
sneez
serou
nasal
discharg
main
sign
acut
oral
upper
respiratori
diseas
sign
mainli
seen
kitten
distinct
syndrom
virul
system
felin
caliciviru
vsfcv
diseas
occasion
describ
coyn
et
al
incub
period
infect
cat
expos
shelter
hospit
day
home
environ
may
day
diseas
appear
sever
adult
kitten
vaccin
current
vaccin
protect
cat
field
infect
protect
shown
experiment
poulet
lemet
huang
et
al
might
due
inher
characterist
hypervirul
strain
kill
vsfcv
strain
vaccin
avail
usa
contain
tradit
vsfcv
isol
report
provid
protect
homolog
vsfcv
huang
et
al
known
strain
vsfcv
provid
protect
heterolog
vsfcv
strain
use
kill
vaccin
rule
individu
dog
cat
protect
mass
canin
vaccin
programm
kill
vaccin
easier
manag
live
prepar
stabil
ambient
temperatur
accid
selfinocul
repres
risk
would
case
mlv
vaccin
canin
felin
rabi
control
mostli
use
inactiv
vaccin
howev
usa
europ
recombin
canari
pox
vector
rabi
vaccin
licens
wide
use
cat
associ
inflamm
inject
site
caus
adjuv
rabi
vaccin
initi
rabi
vaccin
must
follow
year
later
revaccin
second
vaccin
interv
revaccin
extend
legal
year
product
doi
label
doi
natur
infect
assess
diseas
follow
street
viru
infect
fatal
dog
cat
doi
vaccin
commerci
avail
inactiv
recombin
product
year
base
challeng
serolog
studi
ja
et
al
first
vaccin
earlier
week
age
revaccin
year
later
antibodi
titr
gener
reach
protect
level
week
vaccin
serolog
test
requir
legal
purpos
interv
vaccin
test
crucial
may
productdepend
product
datasheet
legal
requir
consult
vaccin
proven
protect
virul
rabi
viru
challeng
year
nation
local
legisl
may
call
annual
booster
vgg
encourag
legisl
consid
scientif
advanc
formul
polici
vaccin
eg
nation
produc
product
may
reliabl
protect
year
presenc
serum
antibodi
iuml
activ
immun
dog
age
week
correl
protect
achiev
concentr
iuml
also
consid
legal
requir
pet
travel
countri
includ
serolog
test
postvaccin
protocol
movement
pet
diseas
fact
sign
diseas
appear
week
sever
month
infect
depend
upon
site
infect
transmiss
gener
bite
scratch
unexplain
aggress
behaviour
sudden
behaviour
chang
must
consid
suspici
diseas
manifest
furiou
dumb
form
sign
classic
furiou
form
rabi
includ
reduc
palpebr
corneal
pupillari
reflex
strabismu
drop
jaw
saliv
pica
seizur
twitch
tremor
disorient
aimless
pace
aimless
snap
bite
exagger
emot
respons
irrit
rage
fear
photophobia
well
ataxia
paralysi
ultim
follow
coma
death
respiratori
arrest
dumb
form
rabi
common
dog
cat
present
lower
motor
neuron
paralysi
progress
site
bite
injuri
involv
entir
central
nervou
system
paralysi
rapidli
lead
coma
death
respiratori
failur
environ
viru
quickli
lose
infect
readili
inactiv
use
detergentbas
disinfect
question
relat
vaccin
product
may
give
mlv
product
wild
exot
speci
domest
speci
one
vaccin
licens
protect
never
give
mlv
vaccin
unless
shown
safe
speci
mani
mlv
vaccin
caus
diseas
anim
speci
licens
even
wors
vaccin
could
shed
wild
anim
regain
virul
multipl
passag
caus
diseas
even
target
speci
develop
safe
effect
vaccin
speci
suscept
cdv
canarypox
virusvector
recombin
cdv
vaccin
avail
monoval
product
ferret
combin
product
dog
monoval
vaccin
use
mani
wild
exot
speci
suscept
cdv
avail
certain
countri
due
insuffici
amount
viru
human
mv
vaccin
immunogen
puppi
measl
viru
vaccin
made
specif
dog
sometim
combin
cdv
addit
viral
compon
may
give
temporari
protect
earlier
age
cdv
vaccin
week
older
puppi
must
vaccin
cdv
vaccin
achiev
perman
immun
ye
heterotyp
measl
vaccin
dog
immun
pup
week
earlier
mlvcdv
vaccin
similarli
canarypox
vector
recombin
cdv
vaccin
immun
approxim
week
earlier
mlv
vaccin
high
titr
mlv
vaccin
ie
vaccin
contain
greater
mass
viru
vaccin
ampoul
also
immun
earlier
age
puppi
mda
ye
mda
block
certain
kill
vaccin
kill
product
requir
two
dose
often
case
first
dose
block
mda
second
dose
immun
circumst
second
dose
prime
block
third
dose
requir
immun
boost
true
mlv
vaccin
absenc
mda
take
singl
dose
prime
immun
boost
nevertheless
two
dose
often
recommend
particularli
young
anim
sure
one
given
mda
wane
block
puppi
kitten
seri
last
dose
given
week
age
older
told
certain
canin
mlv
combin
core
product
need
given
twice
last
dose
age
young
week
accur
vgg
awar
certain
canin
vaccin
licens
earli
finish
order
allow
pup
benefit
earli
social
vgg
accept
import
puppi
social
reserv
immunolog
valid
approach
vaccin
combin
core
product
current
avail
immun
accept
percentag
puppi
particularli
last
dose
given
week
age
vgg
advis
wherev
possibl
last
dose
given
week
age
older
regardless
number
dose
given
earlier
vgg
recommend
owner
pup
complet
full
puppi
vaccin
seri
care
control
exposur
pup
environ
outsid
home
permit
contact
healthi
fulli
vaccin
dog
room
temperatur
sensit
vaccin
eg
cdv
lose
abil
immun
hour
wherea
compon
remain
immunogen
sever
day
eg
cpv
fpv
vgg
recommend
mlv
vaccin
reconstitut
use
within
hr
anim
gone
beyond
time
gener
consid
minimum
doi
core
vaccin
year
cdv
year
fpv
start
seri
vaccin
multipl
dose
week
apart
mlv
vaccin
multipl
dose
requir
puppi
kitten
mda
vgg
awar
mani
data
sheet
advis
restart
vaccin
seri
endors
practic
inconsist
fundament
immun
system
function
principl
immunolog
memori
felv
fiv
posit
cat
clinic
well
would
ideal
hous
indoor
away
cat
minim
risk
exposur
infecti
diseas
howev
deem
necessari
vaccin
core
compon
fpv
fcv
expert
group
current
recommend
kill
mlv
vaccin
cat
vaccin
felv
fiv
felv
fiv
posit
cat
clinic
ill
vaccin
countri
legal
requir
rabi
vaccin
would
also
includ
retrovirusinfect
cat
felin
vaccin
particularli
adjuv
product
given
interscapular
region
usa
practic
give
separ
inject
rabi
vaccin
distal
right
hind
limb
felv
vaccin
distal
left
hind
limb
core
fpvfcv
vaccin
distal
forelimb
practic
altern
site
subcutan
inject
distal
tail
later
thorac
abdomin
wall
option
discuss
main
text
document
whichev
site
chosen
vaccin
must
administ
subcutan
intramuscularli
importantli
anatom
site
felin
vaccin
rotat
vaccin
given
repeatedli
one
locat
may
achiev
record
site
vaccin
individu
occas
rotat
adopt
practic
polici
use
one
anatom
locat
year
ye
shown
certain
sever
defici
vitamin
trace
miner
eg
vitamin
eselenium
interfer
develop
protect
immun
respons
puppi
known
suspect
nutrit
defici
correct
appropri
nutrit
supplement
anim
revaccin
ensur
adequ
protect
immun
depend
antibodi
titr
dam
littl
like
protect
approxim
passiv
antibodi
newborn
puppi
kitten
obtain
colostrum
absorb
via
intestin
system
circul
hour
birth
puppi
kitten
fail
receiv
colostrum
vaccin
first
week
life
sinc
matern
deriv
antibodi
block
activ
immun
puppi
kitten
less
week
age
vaccin
mlv
core
vaccin
certain
modifi
live
vaccin
virus
given
puppieskitten
less
week
age
without
mda
infect
central
nervou
system
andor
caus
diseas
possibl
death
anim
occur
littl
thermoregulatori
control
bodi
temperatur
first
week
birth
thu
innat
adapt
immun
significantli
impair
artifici
colostrum
fed
puppi
kitten
less
day
old
artifici
colostrum
milk
replac
eg
esbilac
tm
similar
product
immun
serum
prefer
dam
well
vaccin
anim
live
environ
dam
pup
kitten
older
day
age
serum
well
immun
adult
anim
free
infecti
diseas
given
subcutan
intraperiton
citrat
plasma
given
intraven
depend
size
anim
approxim
ml
serum
plasma
administ
twice
daili
day
core
vaccin
current
recommend
lifelong
revaccin
frequent
everi
year
noncor
vaccin
chosen
use
gener
given
annual
one
use
serolog
test
adult
dog
confirm
protect
journal
small
anim
practic
vol
januari
wsava
core
diseas
ie
cdv
cav
elect
revaccin
anim
current
advic
serolog
assess
perform
everi
year
dog
older
year
done
annual
mani
countri
also
legal
requir
vaccin
rabi
particular
interv
core
vaccin
singl
dose
mlv
vaccin
cdv
plu
rabi
endem
area
need
give
two
dose
revaccin
serolog
test
cdv
cav
frequent
everi
year
thereaft
noncor
vaccin
select
base
risk
benefit
analysi
individu
anim
noncor
vaccin
would
requir
two
dose
given
week
apart
annual
booster
ye
dog
would
requir
two
dose
vaccin
given
week
apart
annual
revaccin
thereaft
adult
cat
never
vaccin
vgg
recommend
core
vaccin
two
dose
mlv
vaccin
fpv
fcv
plu
one
dose
rabi
vaccin
endem
area
revaccin
serolog
test
fpv
frequent
everi
thereaft
lowrisk
cat
revaccin
frequent
everi
year
fpv
annual
fcv
highrisk
cat
noncor
vaccin
select
base
risk
benefit
analysi
individu
anim
cat
current
clinic
diseas
vaccin
recov
cat
natur
immun
fcv
fhv
agent
involv
caus
respiratori
diseas
immun
never
steril
even
vaccin
indic
vaccin
cat
recov
respiratori
viral
infect
trival
vaccin
protect
fpv
also
respiratori
viru
fcv
involv
caus
earlier
respiratori
diseas
power
cut
uncommon
part
countri
last
day
one
regard
vaccin
fridg
time
ok
use
mlv
vaccin
store
appropri
temperatur
day
use
compon
vaccin
eg
cdv
temperatur
sensit
may
inactiv
viru
doubt
contact
manufactur
advic
ye
particularli
case
cdv
dog
fpv
cat
legal
purpos
rabi
viru
cat
dog
serum
antibodi
titr
limit
valu
vaccin
assay
cmi
littl
valu
vaccin
variou
technic
biolog
reason
factor
less
issu
serolog
test
much
easier
control
mani
variabl
howev
discrep
result
still
obtain
depend
qualiti
assur
program
given
laboratori
question
relev
puppi
adult
dog
like
alreadi
serum
antibodi
present
time
booster
vaccin
regardless
long
interv
sinc
last
vaccin
puppi
receiv
final
primari
vaccin
week
age
may
test
week
age
onward
antibodi
present
stage
passiv
matern
origin
therefor
indic
puppi
activ
protect
mani
veterinarian
question
may
littl
practic
consequ
regular
rabi
vaccin
dog
cat
legal
requir
mani
countri
irrespect
titr
result
rabi
antibodi
test
requir
certain
situat
relat
intern
pet
travel
intern
rabi
vaccin
highli
efficaci
gener
consid
need
demonstr
immun
post
vaccin
